Italian researchers have been able to identify the genetic basis of susceptibility to Covid-19 infection, and also to the possibility of contracting a more severe form of the disease. This has important implications for treatment and drug development.

Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.

Cystic fibrosis is the most frequent severe inherited disorder worldwide. Researchers have now discovered a novel disease that might lead to a better understanding of cystic fibrosis and new treatment options in the future.

Insight Knowledge is an STM (Science, Technology and Medicine) publisher, manages and disseminates knowledge through scientific journals. We provide high quality services and strive to ease all steps from submission to publication of high quality research work. Insight Knowledge is working with the commitment to bring the highest quality research to the widest possible audience and share the research work in a timely fashion.

Insight Knowledge Limited is a company incorporated in England and Wales under company number 09292454 and whose registered office is located at 20-22 Wenlock Road, London, N1 7GU, England.